The new test will detect the gene mutations in whole blood and bone marrow samples from AML patients. Credit: Lucas Vasques / Unsplash.

Qiagen and Servier have entered a strategic collaboration for the development of a new companion diagnostic test for isocitrate dehydrogenase-1 (IDH1) inhibitor, Tibsovo, which is indicated to treat the blood cancer acute myeloid leukaemia (AML).

Under the deal, Qiagen will develop and validate a new real-time in vitro polymerase chain reaction (PCR)-based diagnostic test.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test will be used for the detection of IDH1 gene mutations in whole blood and bone marrow samples from patients with AML.

It will be used with the marketed and investigational targeted treatments of Servier.

Qiagen Partnering for Precision Diagnostics head and vice-president Jonathan Arnold said: “Patients with AML may deteriorate rapidly if not treated quickly so we are pleased to support Servier with a companion diagnostic in their mission to propose innovative treatment for IDH1 mutated AML patients.

“At the same time, we are further strengthening our role in developing companion diagnostics for the ever-growing number of biomarkers being discovered in onco-haematology.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new test will run on the Qiagen Rotor-Gene Q MDx device, which is said to be widely used in laboratories around the world.

Clinical validation and approval of the diagnostic in Japan, the European Union and the US will be supported by Qiagen’s regulatory teams.

Servier Companion Diagnostics global head Brian Lockhart said: “In order to expand the global access for Tibsovo for patients, it is imperative that we leverage a partner, such as Qiagen, with an established global footprint in oncology-driven diagnostics, and a proven expertise in companion diagnostics development and approvals.”

Qiagen currently has master collaboration agreements with more than 30 companies for the development and commercialisation of companion diagnostics.